GlassScriptPhysician profile
Kelly Owen
NPI 1255082673
$17,169.36
in general payments reported to CMS, 2019-2025
68 companies · $4,698 in 2025
The $4,698 reported for 2025 was more than what 99% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $3,595 · 2023: $4,166 · 2024: $4,710 · 2025: $4,698.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Long Term Medical Supply Or Device Loan: $2,030 · Education: $1,077.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,467.46 |
| Long Term Medical Supply Or Device Loan | $2,029.70 |
| Education | $1,077.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,535.74 | 2022-2025 | |
| Janssen Biotech, INC. | $1,375.18 | 2022-2025 | Rybrevant, Erleada, Imbruvica |
| Eisai INC. | $730.89 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $629.78 | 2022-2025 | Opdivo, Reblozyl, Opdualag |
| Astellas Pharma US INC | $626.01 | 2022-2025 | Padcev, Xtandi |
| Incyte Corporation | $565.38 | 2022-2025 | Jakafi, Monjuvi |
| Takeda Pharmaceuticals U.S.A., INC. | $544.19 | 2022-2025 | Alunbrig, Ninlaro, Iclusig |
| Celgene Corporation | $533.91 | 2022-2025 | Pomalyst, Reblozyl, Opdualag |
| Seagen INC. | $502.88 | 2022-2025 | Padcev, Tivdak, Adcetris |
| Sobi, INC | $460.05 | 2022-2025 | |
| Glaxosmithkline, LLC. | $399.97 | 2022-2025 | Ojjaara, Zejula, Shingrix |
| Pfizer INC. | $391.70 | 2022-2025 | |
| Daiichi Sankyo INC. | $358.97 | 2022-2025 | Enhertu, Vanflyta |
| Astrazeneca Pharmaceuticals LP | $347.56 | 2022-2025 | Imfinzi, Lynparza, Calquence |
| Merck Sharp & Dohme LLC | $342.96 | 2022-2025 | Keytruda, Lynparza, Welireg |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $342.39 | 2022-2025 | Xpovio |
| Beigene USA, INC. | $326.16 | 2022-2025 | Brukinsa |
| Regeneron Healthcare Solutions, INC. | $312.71 | 2022-2025 | Libtayo |
| Lilly USA, LLC | $303.11 | 2022-2025 | Verzenio, Jaypirca |
| Pharmacyclics LLC, An Abbvie Company | $281.66 | 2022-2023 | Imbruvica |
| Puma Biotechnology, INC. | $271.38 | 2022-2025 | Nerlynx |
| Gilead Sciences, INC. | $266.09 | 2022-2025 | Trodelvy |
| Amgen INC. | $242.91 | 2022-2025 | Blincyto, Kyprolis, Xgeva |
| Boehringer Ingelheim Pharmaceuticals, INC. | $239.11 | 2022-2025 | Gilotrif |
| Abbvie INC. | $220.81 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $213.24 | 2023-2025 | |
| Genzyme Corporation | $181.78 | 2022-2024 | |
| Array Biopharma INC | $178.81 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Dendreon Pharmaceuticals LLC | $168.96 | 2022-2025 | Provenge |
| Rigel Pharmaceuticals, INC. | $152.34 | 2023-2024 | Tavalisse, Rezlidhia |
| Sumitomo Pharma America, INC. | $140.82 | 2023-2025 | Orgovyx |
| Taiho Oncology, INC. | $127.97 | 2022-2025 | |
| Beone Medicines USA, INC. | $120.32 | 2025 | Brukinsa |
| Myovant Sciences INC. | $118.09 | 2022 | |
| Csl Behring | $105.54 | 2022-2023 | Afstyla, Idelvion |
| Ipsen Biopharmaceuticals, INC | $105.51 | 2023-2025 | Onivyde, Somatuline Depot, Tazverik |
| Alnylam Pharmaceuticals INC. | $102.81 | 2022-2025 | Givlaari |
| Adaptive Biotechnologies Corporation | $102.35 | 2022-2023 | Clonoseq |
| Pharmaessentia USA Corporation | $100.22 | 2024-2025 | Besremi |
| Alexion Pharmaceuticals, INC. | $98.56 | 2022-2025 | Ultomiris |
| Genentech USA, INC. | $94.59 | 2023-2024 | Tecentriq |
| Emmaus Medical, INC. | $88.61 | 2022-2024 | Endari |
| Morphosys, US INC. | $85.68 | 2022-2023 | Monjuvi |
| Emd Serono, INC. | $53.90 | 2023-2024 | Bavencio |
| Immunogen, INC. | $51.70 | 2023 | Elahere |
| Tempus Ai, INC | $46.23 | 2024 | |
| Servier Pharmaceuticals LLC | $45.30 | 2025 | |
| Geron Corporation | $43.53 | 2025 | Rytelo |
| Agios Pharmaceuticals, INC. | $35.80 | 2023-2024 | Pyrukynd |
| Springworks Therapeutics, INC. | $34.22 | 2024 | Ogsiveo |
| Novocure INC. | $34.11 | 2022-2023 | Optune |
| Verity Pharmaceuticals INC. | $30.93 | 2025 | Trelstar |
| Syndax Pharmaceuticals, INC. | $28.50 | 2025 | |
| Legend Biotech USA INC. | $27.63 | 2024 | |
| Kyowa Kirin, INC. | $25.39 | 2022 | |
| Pharmacosmos Therapeutics INC. | $25.37 | 2022 | |
| Progenics Pharmaceuticals, INC. | $25.23 | 2023 | Pylarify |
| Recordati_rare_diseases_inc. | $24.29 | 2024 | Sylvant |
| Blueprint Medicines Corporation | $24.27 | 2024 | Ayvakit |
| Amneal Pharmaceuticals LLC | $23.55 | 2023 | Neulasta, Avastin, Neupogen |
| Sun Pharmaceutical Industries INC. | $23.35 | 2023 | Yonsa, Odomzo |
| Tactile Systems Technology INC | $22.89 | 2025 | Nimbl, Flexitouch Plus |
| Adc Therapeutics America, INC. | $21.56 | 2022 | |
| Aveo Pharmaceuticals, INC. | $21.25 | 2025 | |
| Exelixis INC. | $18.88 | 2022 | |
| Fennec Pharmaceuticals, INC. | $18.05 | 2025 | Fyarro |
| Mirati Therapeutics, INC. | $13.12 | 2023 | Krazati |
| Iovance Biotherapeutics, INC. | $12.61 | 2024-2025 | Amtagvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Owen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.